Medtronic PLC $MDT Shares Purchased by Perpetual Ltd

Perpetual Ltd grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 50.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,520 shares of the medical technology company’s stock after buying an additional 36,896 shares during the period. Perpetual Ltd’s holdings in Medtronic were worth $10,526,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of the business. 1248 Management LLC acquired a new position in Medtronic during the first quarter worth approximately $26,000. Delos Wealth Advisors LLC acquired a new position in Medtronic in the second quarter worth $27,000. Twin Tree Management LP bought a new stake in shares of Medtronic in the 1st quarter worth approximately $29,000. Activest Wealth Management grew its position in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares during the last quarter. Finally, GFG Capital LLC acquired a new position in Medtronic during the 2nd quarter valued at about $36,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Stores Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic filed an S-1 to take its Diabetes unit, MiniMed, public — the preferred separation path is an IPO followed by a split-off. Management says the move is part of a planned separation aimed at creating two focused companies, which could unlock value and provide strategic clarity. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed
• Positive Sentiment: Regulatory and product progress: Medtronic (and peers) secured FDA nods for liquid embolic systems — a reminder the company continues to advance therapeutic devices that can support organic growth beyond the diabetes separation. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems
• Neutral Sentiment: Ownership and structure details may limit immediate financial impact — media reports note Medtronic expects to retain majority voting control (reported at least ~80.1% of voting stock), suggesting the IPO could be more about strategic focus and value crystallization than a full divestiture. Medtronic Spin-Off MiniMed Files for IPO
• Neutral Sentiment: Analyst stances remain cautious: some firms (e.g., Robert W. Baird) are maintaining “hold” ratings, reflecting mixed near-term views even as the strategic move unfolds. Robert W. Baird Remains a Hold on Medtronic (MDT)
• Negative Sentiment: Price-target trim: Truist cut its MDT price target modestly (from $110 to $107) and kept a “hold” rating, a sign some analysts see limited near-term upside despite the strategic separation. This analyst action could cap momentum until clearer financials for MiniMed and separation mechanics are disclosed. Medtronic price target lowered to $107 from $110 at Truist

Medtronic Stock Up 0.2%

Shares of NYSE:MDT opened at $98.63 on Friday. The company has a market capitalization of $126.45 billion, a PE ratio of 26.59, a P/E/G ratio of 2.60 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company’s fifty day moving average is $97.38 and its 200-day moving average is $93.41. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s payout ratio is presently 76.55%.

Analysts Set New Price Targets

MDT has been the topic of several recent research reports. Weiss Ratings restated a “buy (b)” rating on shares of Medtronic in a research report on Monday, December 15th. Wells Fargo & Company raised their price objective on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Leerink Partners set a $120.00 price target on Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Citigroup raised their price target on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Finally, Barclays lifted their price objective on Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).